Trump's Executive Order May Accelerate Psychedelic Therapy Regulation
President Donald Trump signed an executive order to expedite the review of psychedelic therapies for mental health, potentially accelerating regulatory timelines and increasing institutional interest in the sector. Compass Pathways, a company in phase 3 clinical trials with positive late-stage data, is highlighted as a key player in the psychedelics industry.
Topics: biotech investor_impact mental_health psychedelics regulatory_approval